Lisa Bero

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi The updated clinical guideline development process in Estonia is an efficient method for developing evidence-based guidelines
    Lisa A Bero
    Department of Clinical Pharmacy, Institute for Health Policy Studies, University of California, San Francisco, San Francisco, CA 94118, USA
    J Clin Epidemiol 66:132-9. 2013
  2. ncbi Association of trial registration with the results and conclusions of published trials of new oncology drugs
    Nicolas Rasmussen
    History and Philosophy of Science, University of New South Wales, Sydney 2052, Australia
    Trials 10:116. 2009
  3. ncbi Could chiropractors screen for adverse drug events in the community? Survey of US chiropractors
    Monica Smith
    Palmer Center for Chiropractic Research, Palmer College of Chiropractic, Davenport, IA, USA
    Chiropr Osteopat 18:30. 2010
  4. ncbi Evidence and argument in policymaking: development of workplace smoking legislation
    Dorie E Apollonio
    Department of Clinical Pharmacy, University of California San Francisco, San Francisco, CA 94143 0613, USA
    BMC Public Health 9:189. 2009
  5. ncbi Implementation of a workplace smoking ban in bars: the limits of local discretion
    Theresa Montini
    New York University, 423 East 23rd Street, VET 16N, New York, NY 10010, USA
    BMC Public Health 8:402. 2008
  6. ncbi Identifying barriers to the availability and use of Magnesium Sulphate Injection in resource poor countries: a case study in Zambia
    Anna L Ridge
    Medicine Access and Rational Use, Department of Essential Medicines and Pharmaceutical Policies, World Health Organization, Geneva, Switzerland
    BMC Health Serv Res 10:340. 2010
  7. ncbi Factors associated with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than others
    Lisa Bero
    Clinical Pharmacy and Health Policy, University of California, San Francisco, California, United States of America
    PLoS Med 4:e184. 2007
  8. ncbi "Experimental" institutional models for corporate funding of academic research: unknown effects on the research enterprise
    Lisa Bero
    University of California, Clinical Pharmacy and Health Policy, 3333 California Street, Suite 420, San Francisco, CA, USA
    J Clin Epidemiol 61:629-33. 2008
  9. ncbi To give is better than to receive: compliance with WHO guidelines for drug donations during 2000-2008
    Lisa Bero
    Department of Clinical Pharmacy, University of California, 3333 California Street Suite 420, San Francisco, CA 94118, United States of America
    Bull World Health Organ 88:922-9. 2010
  10. ncbi An evidence-based medicine methodology to bridge the gap between clinical and environmental health sciences
    Tracey J Woodruff
    University of California, San Francisco, CA, USA
    Health Aff (Millwood) 30:931-7. 2011

Collaborators

Detail Information

Publications17

  1. ncbi The updated clinical guideline development process in Estonia is an efficient method for developing evidence-based guidelines
    Lisa A Bero
    Department of Clinical Pharmacy, Institute for Health Policy Studies, University of California, San Francisco, San Francisco, CA 94118, USA
    J Clin Epidemiol 66:132-9. 2013
    ..This experience may be relevant to other small or resource-limited countries...
  2. ncbi Association of trial registration with the results and conclusions of published trials of new oncology drugs
    Nicolas Rasmussen
    History and Philosophy of Science, University of New South Wales, Sydney 2052, Australia
    Trials 10:116. 2009
    ..This study compares the prevalence of favorable results and conclusions among published reports of registered and unregistered randomized controlled trials of new oncology drugs...
  3. ncbi Could chiropractors screen for adverse drug events in the community? Survey of US chiropractors
    Monica Smith
    Palmer Center for Chiropractic Research, Palmer College of Chiropractic, Davenport, IA, USA
    Chiropr Osteopat 18:30. 2010
    ....
  4. ncbi Evidence and argument in policymaking: development of workplace smoking legislation
    Dorie E Apollonio
    Department of Clinical Pharmacy, University of California San Francisco, San Francisco, CA 94143 0613, USA
    BMC Public Health 9:189. 2009
    ..We sought to identify factors that affect the passage of public health legislation by examining the use of arguments, particularly arguments presenting research evidence, in legislative debates regarding workplace smoking restrictions...
  5. ncbi Implementation of a workplace smoking ban in bars: the limits of local discretion
    Theresa Montini
    New York University, 423 East 23rd Street, VET 16N, New York, NY 10010, USA
    BMC Public Health 8:402. 2008
    ..In January 1998, the California state legislature extended a workplace smoking ban to bars. The purpose of this study was to explore the conditions that facilitate or hinder compliance with a smoking ban in bars...
  6. ncbi Identifying barriers to the availability and use of Magnesium Sulphate Injection in resource poor countries: a case study in Zambia
    Anna L Ridge
    Medicine Access and Rational Use, Department of Essential Medicines and Pharmaceutical Policies, World Health Organization, Geneva, Switzerland
    BMC Health Serv Res 10:340. 2010
    ..The objective of this study was to identify barriers to the availability and use of MgSO4 in the Zambian Public Health System...
  7. ncbi Factors associated with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than others
    Lisa Bero
    Clinical Pharmacy and Health Policy, University of California, San Francisco, California, United States of America
    PLoS Med 4:e184. 2007
    ....
  8. ncbi "Experimental" institutional models for corporate funding of academic research: unknown effects on the research enterprise
    Lisa Bero
    University of California, Clinical Pharmacy and Health Policy, 3333 California Street, Suite 420, San Francisco, CA, USA
    J Clin Epidemiol 61:629-33. 2008
  9. ncbi To give is better than to receive: compliance with WHO guidelines for drug donations during 2000-2008
    Lisa Bero
    Department of Clinical Pharmacy, University of California, 3333 California Street Suite 420, San Francisco, CA 94118, United States of America
    Bull World Health Organ 88:922-9. 2010
    ..to assess drug donations in terms of their adherence to the drug donation guidelines put forth by the World Health Organization (WHO)...
  10. ncbi An evidence-based medicine methodology to bridge the gap between clinical and environmental health sciences
    Tracey J Woodruff
    University of California, San Francisco, CA, USA
    Health Aff (Millwood) 30:931-7. 2011
    ..The methodology can also support professional societies, health care organizations, government agencies, and others in developing prevention-oriented guidelines for use in clinical and policy settings...
  11. ncbi Effect of reporting bias on meta-analyses of drug trials: reanalysis of meta-analyses
    BETH HART
    Department of Clinical Pharmacy, Institute for Health Policy Studies, University of California, San Francisco, 3333 California St, Suite 420, San Francisco, CA 94118, USA
    BMJ 344:d7202. 2012
    ..To investigate the effect of including unpublished trial outcome data obtained from the Food and Drug Administration (FDA) on the results of meta-analyses of drug trials...
  12. ncbi Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation
    Kristin Rising
    School of Medicine, University of California San Francisco, San Francisco, California, USA
    PLoS Med 5:e217; discussion e217. 2008
    ....
  13. ncbi Tobacco industry research and protection of human subjects: a case study of R. J. Reynolds
    Jenny White
    Department of Clinical Pharmacy, University of California, San Francisco, CA, USA
    Nicotine Tob Res 9:1213-25. 2007
    ..Policymakers should consider expanding the scope of federal human subjects research regulations to cover research undertaken by private firms such as tobacco companies...
  14. ncbi Financial ties and conflicts of interest between pharmaceutical and tobacco companies
    Bhavna Shamasunder
    Institute for Health Policy Studies, University of California, San Francisco, USA
    JAMA 288:738-44. 2002
    ..Thus, because tobacco cessation product marketing has been altered as a result of these financial conflicts, disclosure would serve the interest of public health...
  15. ncbi Implications of the tobacco industry documents for public health and policy
    Lisa Bero
    Department of Clinical Pharmacy, Institute for Health Policy Studies, University of California, San Francisco, California 94143 0613, USA
    Annu Rev Public Health 24:267-88. 2003
    ..The paper concludes with a discussion of the implications of tobacco document research for public health and the application of such research to fields other than tobacco control...
  16. ncbi Applying the essential medicines concept to US preferred drug lists
    Timothy P Millar
    Department of Clinical Pharmacy, University of California, San Francisco, CA, USA
    Am J Public Health 101:1444-8. 2011
    ..We also characterized listed medicines by generic availability and appearance on treatment guidelines...
  17. ncbi Clarification of study and citation
    Patrick R Finley
    Arch Intern Med 167:2531; author reply 2531-2. 2007